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Bupropion is an antidepressant used in the treatment of smoking. The purpose of this study was to 
prepare controlled-release hydrogel films for buccal administration of bupropion and investigate 
its physicochemical and cytotoxic properties. The films were prepared from ultrapure sodium 
carboxymethylcellulose, hydroxypropylmethylcellulose K4M, and medium-viscosity chitosan. Evaluation 
of film physicochemical characteristics was based on scanning electron microscopy, bupropion content, 
mechanical strength (burst strength, relaxation, resilience, and traction), and cytotoxicity. Bupropion 
content in bilayer films was 121 mg per 9 cm2. The presence of bupropion modified film mechanical 
strength, but did not compromise the use of this pharmaceutical form. As shown by the cytotoxicity 
results, films containing bupropion did not cause cellular damage. Bupropion administration in the form 
of hydrogel films is a potentially useful alternative in the treatment of smoking.
Uniterms: Bupropion/buccal administration. Bilayer films/drugs rellease. Drugs/controlled-release. 
Tobacco/control.
A bupropiona é um antidepressivo utilizado no tratamento do tabagismo. O objetivo deste trabalho foi a 
preparação de filmes hidrogelatinosos de liberação controlada para administração bucal de bupropiona. Os 
filmes foram preparados utilizando carboximetilcelulose sódica ultrapurificada, hidroxipropilmetilcelulose 
K4M e quitosana de média viscosidade. As características físico-químicas dos filmes foram avaliadas por 
microscopia eletrônica de varredura, teor de bupropiona, resistência mecânica (perfuração, relaxação, 
resiliência e tração) e citotoxicidade. Os resultados mostraram que os filmes em bicamada apresentaram 
teor de bupropiona de 121 mg por 9 cm2 de filme e que a bupropiona modifica a resistência mecânica 
dos filmes, sem, no entanto, inviabilizar o uso desta forma farmacêutica. Os estudos de citotoxicidade 
mostraram que as formulações dos filmes contendo bupropiona não causam dano celular. Este estudo 
mostrou que a bupropiona veiculada na forma de filme hidrogelatinoso pode ser uma alternativa útil no 
tratamento do tabagismo.
Unitermos: Bupropiona/administração bucal. Filmes em bicamada/liberação de fármacos. Fármacos/
liberação controlada. Tabagismo/controle.
INTRODUCTION
Smoking is one of the most important risk factors 
for developing cardiovascular disease (Jonas et al., 
1992). Approximately 92% of smokers are aware of 
the detrimental effects of smoking, and stopping this 
habit reduces the risk of developing chronic diseases 
(Jonas et al., 1992). About 70% of smokers want to stop 
smoking, yet only 5% to 10% are successful. Studies on 
the simultaneous use of nicotine and bupropion have 
reported smoking cessation within six months (Gold, 
Rubey, Harvey, 2002; Jorenby et al., 1999).
Bupropion (RS-2-( ter t-butylamino)-1-(3-
chlorophenyl) propan-1-one) has been prescribed as an 
antidepressant (Cicardo et al., 1986) and was the first 
non-nicotinic drug used therapeutically against smoking 
(Paganelli et al., 2006). While most antidepressants 
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selectively inhibit serotonin reuptake inhibitors or 
monoamine oxidase activity, bupropion inhibits dopamine 
uptake and noradrenaline (Ascher et al., 1995). Dopamine 
and catecholamine are involved in the symptoms of 
withdrawal syndrome (Ascher et al., 1995; Gobbi et al., 
2003). Bupropion has a less potent effect on cardiac function 
than tricyclic antidepressants, but no anticholinergic or 
sympathomimetic effects (Soroko, Maxwell, 1983).
Although bupropion effectiveness and safety have 
been demonstrated (Roose et al., 1991; Holt et al., 2005), 
its pharmacological profile, dosage and administration, as 
well as its tolerability, clinical effectiveness, and safety for 
some groups of patients have been discussed, particularly 
when the drug is administered to cardiac smokers 
(Thompson, Rigotti, 2003) or patients with chronic 
obstructive pulmonary disease (Tonstad, Johnston, 2004). 
Paganelli et al. (2006) showed that at doses commonly 
used in humans (3 to 6 mg/kg) the compound caused 
pulmonary hypertension in normal dogs.
B u p r o p i o n  i s  p r o m p t l y  a b s o r b e d  i n  t h e 
gastrointestinal tract. Plasma concentrations peak in 3 h, 
remaining elevated in cases of renal failure. Bupropion 
undergoes extensive hepatic biotransformation by 
hydroxylation of tert-butyl and/or reduction of carbonyl 
groups. This hepatic metabolism is mediated by CYP2B6 
and cytochrome P45. Its normal half-life of 21 h is 
extended in hepatic impairment. Approximately 84% of 
absorbed bupropion binds to plasma proteins, but release 
is slow (Reichert et al., 2008).
Buccal administration has been used for compounds 
that undergo extensive hepatic first-pass metabolism or 
that are poorly stable in the gastrointestinal environment. 
Hydroxybupropion, a metabolite of bupropion, is less 
effective than its parent compound, despite having 
similar potency (Hardman, Limbird, 2003; Rang, Dale, 
2007). Hydrogel films provide a more effective manner 
of controlling drug dosages for buccal administration 
than other pharmaceutical forms (Semalty, Semalty, 
Nautiyal, 2010; Nappinnai, Chandanbala, Balaijirajan, 
2008). Buccal administration can promote rapid, yet 
prolonged, responses, ensuring drug delivery to patients 
with swallowing difficulties (Nerkar, Gattani, 2012; Park 
et al., 2012).
In mucoadhesive hydrogel films, fast drug release is 
ensured by prompt hydrogel dissolution, while the slow 
erosion of polymers facilitate controlled release (Cid et 
al., 2012; Giovino et al., 2012; Wu et al., 2012; Yuan et 
al., 2011).
Mucoadhesive films have been widely studied for 
oral drug absorption and can be potentially employed in 
the treatment of diabetes (glipizide and insulin carriers), 
hypertension, and angina pectoris (enalapril maleate, 
nitrendipine), oral candidiasis (fluconazole, clotrimazole), 
asthma (salbutamol), and Alzheimer’s disease (donepezil) 
(Semalty, Semalty, Kumar, 2008; Sahni et al., 2008; 
Semalty, Semalty, Nautiyal, 2010; Nappinnai, Chandanbala, 
Balaijirajan, 2008; Singh et al., 2008, 2010; Yehia, El-
Gazayerly, Basalious, 2009).
Preparing hydrogel bilayer films is a strategy to 
promote peak concentration within minutes while ensuring 
prolonged effect. This allows bupropion (with a half-life 
of 21 h) and its metabolites (20-37 h half-lives) to be 
administered only once daily.
The purpose of this study was to develop a 
suitable dosage form for buccal administration of 
bupropion. The mechanical properties, drug content, 
and cytotoxicity of hydrogel films containing bupropion, 
ultrapure sodium carboxymethylcellulose (CMC), 
hydroxypropylmethylcellulose K4M (HPMC), and 
medium-viscosity chitosan (MVC) were evaluated.
MATERIAL AND METHODS
All compounds employed—namely, Highly Purified 
sodium carboxymethylcellulose (CPKelco, Limeira, 
Brazil), hydroxypropylmethylcellulose (Methocel K4M®, 
Colorcon, Cotia, Brazil), Medium-viscosity chitosan 
(Sigma-Aldrich, São Paulo, Brazil), and bupropion 
hydrochloride (Dipharma Francis, Italy), were of 
pharmaceutical purity.
Preparation of hydrogels
Hydrogels compositions are shown in Table I. 
Formulations F1, F3, and F4 were prepared by dispersing 
the polymer and other components in purified water. 
The mixture was homogenized, mechanically stirred 
at 7000 rpm (T-25D Ultra Turrax disperser, IKA) for 
5 min or until polymer lumps disappeared, and left to 
stand at 10 °C for 24 h for spontaneous elimination of air 
bubbles. Formulation F2, containing MVC, was prepared 
by dispersing this polymer in 0.1 M acetic acid. The 
dispersion was subjected to orbital stirring at 150 rpm for 
48 h. For formulations containing bupropion (F3, F4), 
the drug was previously dissolved in purified water and 
incorporated into the HPMC K4M hydrogel.
To achieve the desired physical and chemical 
characteristics, F1, F2, and F3A were blended at a 
1.5:4.5:15.0 (m/m) ratio, respectively, for preparation of 
the drug-amended hydrogel (mixture A). F1, F2, and F3B 
were blended at a 1.5:4.5:15.0 (m/m) ratio, respectively, to 
yield the placebo hydrogel (mixture B). The mixtures thus 
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TABLE I - Composition of hydrogels
Components F1 F2 F3A F3B F4A F4B
Sodium carboxymethylcellulose 2% - - - - -
Hydroxypropylmethylcellulose K4M - - 3.75% 3.75% 3.75% 3.75%
Medium-viscosity chitosan - 2% - - - -
Acetic acid, 0.1 M - 50 mL - - - -
Sorbitol 0.5% - 0.5% 0.5% 0.5% 0.5%
Propylene glycol 0.5% - 0.5% 0.5% 0.5% 0.5%
Hydrogenated castor oil 0.5% - 0.5% 0.5% 0.5% 0.5%
Sodium cyclamate 0.5% 0.5% 0.5% 0.5% 0.5%
Sodium chloride 0.5% - 0.5% 0.5% 0.5% 0.5%
Citric acid 0.5% - 0.5% 0.5% 0.5% 0.5%
Dye 10 drops - 10 drops 10 drops 10 drops 10 drops
Flavor 30 drops - 30 drops 30 drops 30 drops 30 drops
Bupropion hydrochloride - - 9g - 27g -
Purified water 100 mL - 100 mL 100 mL 100 mL 100 mL
prepared were left to rest at 10 °C for 24 h for spontaneous 
elimination of air bubbles.
Characterization of hydrogels with and without 
bupropion
The resulting hydrogels underwent hydrogen ion 
concentration (pH) and viscosity measurements. For pH 
measurements (performed on a model 300 pH-meter, 
Analyzer, São Paulo, Brazil), they were dispersed at 
10% in previously neutralized water. All measurements 
were performed in triplicate and recorded as log values. 
Viscosity was measured using a digital viscometer (I RDV 
Prime, Brookfield, São Paulo) equipped with an adapter 
for small samples. A coaxial spindle (SC4-28, Brookfield, 
São Paulo) was employed, and viscosity was measured 
at a constant temperature of 25 °C in a thermostatic bath 
(TC-550, Brookfield, São Paulo).
Preparation of hydrogel films
Mixtures A and B were separately used to prepare 
the films, employing a 12 cm–long, 3 cm–high acrylic 
dispenser (working volume: 30 cm³) with a 3 mm–wide slit 
on the lower face, from which the hydrogel was dispensed 
onto a degreased glass plate while the dispenser was 
moved against it at constant speed.
The films thus obtained (film A: bupropion-amended 
monolayer; film B: placebo monolayer) were weighed 
and kept at 23-25 °C in a dry atmosphere (60-70% RH) 
protected from light and environmental impurities. 
Upon reaching constant weight, as confirmed by three 
consecutive measurements at 60 min intervals, the films 
were removed from the glass plates, cut into 9 cm2 pieces, 
and tightly sealed in laminated packaging material.
Preparation of bilayer films
To prepare the bilayer films, the hydrogel mixtures 
(MA and MB) were blended and spread on a degreased 
glass using the same equipment described for the monolayer 
films. The plate was kept at room temperature (23-25 °C) 
in a dry place (60-70% RH) protected from light and 
environmental impurities, until reaching constant weight. 
Once the films had dried completely, formulation F4A 
(Table I) was spread on film A (Figure 4) and Formulation 
4B (Table I) on film B (Figure 4) using a 18 cm³ dispenser 
with a 1 mm–wide slit on the lower face. The glass plate 
was maintained at room temperature (23-25 °C) in a dry 
place (60-70% RH), protected from light and environmental 
impurities, until reaching constant weight. The bilayer film 
was removed from the plate and cut into 9 cm² pieces for 
evaluation of mechanical resistance and cytotoxicity, pH 
measurement, and content quantification.
Characterization of films with and without 
bupropion
Because discontinuous films are not resistant to 
handling, the evaluation of physicochemical and cytotoxic 
properties was preceded by selection of film samples, 
based on macroscopic appearance. Samples containing 
air bubbles, thickness variability exceeding 5%, or small 
superficial incisions were discarded.
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Measurement of weight and thickness of bilayer 
films containing bupropion
The samples of films containing bupropion were 
weighed on an analytical balance (DV215CD, Ohaus, 
São Paulo). The samples were cut into 9 cm² pieces and 
weighed. Film thickness was measured with calipers 
(150 mm, stainless steel, Lee Tools, São Paulo) at five 
points, one at each corner of the piece and one at its center. 
Weight and thickness were measured in triplicate.
Measurement of pH of bilayer films containing 
bupropion
For quantification of hydrogen ion concentrations, 
the film pieces were dissolved in 10 mL of purified water 
previously neutralized. The procedure was performed in 
triplicate and the results were recorded as log values.
Mechanical properties
The mechanical properties (burst strength, relaxation, 
resilience and traction) of mono- and bilayer placebo 
films and mono- and bilayer bupropion-amended films 
were evaluated in triplicate using a texturometer (TA-TX 
Plus, Stable Micro Systems, UK; Extralab, Brazil). The 
parameters adopted to evaluate the mechanical properties 
are listed in Table II.
To evaluate tensile strength, the ends of the 9 cm2 
film pieces were fixed by clamps (mini tensile grips) with 
brackets positioned 3 cm apart. The internal surfaces of the 
tabs covered with double-face adhesive tape to minimize 
the effect of the tab grooves on film resistance.
The films were tested for burst strength, resistance, 
resilience, and relaxation against a spherical probe with 
a 0.25 mm diameter. For this purpose, a film piece was 
placed between two perforated plates firmly attached to 
the equipment base. In the burst strength test, compressive 
strength was recorded at film rupture. In the resilience 
test, resilience was calculated (as percentage) by the 
equipment’s software, which also calculated retained 
strength (as percentage) in the relaxation test.
Film morphology
T h e  p l a c e b o  f i l m s  w e r e  e v a l u a t e d  b o t h 
macroscopically and by SEM, using a 6390LV device 
(JEOL USA). SEM images were captured for the top, 
bottom, and lateral surfaces. To obtain the lateral views the 
films were cross-sectioned. The film samples were fixed 
on one side of a double-face adhesive tape set against an 
aluminum support. The carrier containing the film was 
coated with gold ions, the top layer of which was deposited 
in a vacuum at 3 mA electrical conductivity for 3 min, to 
a total thickness of ~150 Å.
Bupropion analytical curve
The analytical curve was obtained from aqueous 
solutions of bupropion at 20, 60, 100, 140, and 
180 μg/mL. Bupropion concentrations in the solutions 
were determined by UV spectroscopy (800XI UV/Vis, 
Femto, São Paulo) at λ = 252 nm (BRAZIL, 2010a). The 
average absorbance (n = 3) for each concentration was 
calculated and employed to evaluate linearity and obtain 
the curve equation.
TABLE II – Parameters adopted to evaluate the mechanical properties of films
Parameters
Mechanical properties of resistance
Traction Burst strength Resilience Relaxation
Apparatus Mini tensile grip (part 
code A/MTG; batch 
13101)
Film support rig (part 
code HDP/FSR; batch 
13085)
Film support rig (part 
code HDP/FSR; batch 
13085)
Film support rig (part 
code HDP/FSR; batch 
13085)
Test mode Tension Compression Compression Compression
Pre-test speed 1 mm/s 2 mm/s 1 mm/s 1 mm/s
Test speed 2 mm/s 1 mm/s 0.5 mm/s 0.5 mm/s
Post-test speed 10 mm/s 10 mm/s 0.5 mm/s 10 mm/s
Target mode Distance Distance Distance Distance
Distance 10 mm 5 mm 2 mm 2 mm
Trigger type Auto Auto Auto Auto
Trigger force 5 g 5 g 5 g 5 g
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TABLE III – Mean pH and viscosity values of hydrogels
Formulation pH Viscosity (cP)
F1 4.24 ± 0.02 6833 ± 0042
F2 4.18 ± 0.19 2210 ± 0084
F3A 2.92 ± 0.10 6225 ± 0169
F3B 2.78 ± 0.05 7175 ± 0074
F4A 2.55 ± 0.12 6850 ± 0183
F4B 2.78 ± 0.07 7175 ± 0046
Mixture A (F1, F2, and F3A) 3.75 ± 0.09 6600 ± 0130
Mixture B (F1, F2, and F3B) 3.56 ± 0.15 7725 ± 0042
Bupropion content of bilayer films
Bupropion content in the films was calculated by 
applying the curve equation, after determining bupropion 
concentrations by UV (λ = 252 nm). Briefly, a 9 cm² sample 
of film was dissolved in purified water to a theoretical 
bupropion concentration of 83 μg/mL (Brazil, 2010). The 
samples were randomly selected and the procedure was 
performed in triplicate.
Evaluation of cell viability
Cell viability was evaluated in human bone 
marrow lymphoblasts (cell line K-562). The cells were 
thawed and placed in culture flasks containing RPMI 
medium supplemented with 10% fetal bovine serum, 
required for replication. After 24 h the cells were plated 
in 6-well culture plates at 1105 cells/mL. The cells were 
then exposed to placebo monolayer, placebo bilayer, 
bupropion monolayer, or bupropion bilayer films for 24 h. 
Negative controls were cell not exposed to any films. Cell 
viability tests were performed at 6 and 24 h of exposure. 
Viability was evaluated in a 150 µL sample using a Tali 
image-based cytometer (Life Technologies). The sample 
was centrifuged for 5 min at 1500 rpm, the supernatant 
discarded, and the precipitate treated using a Tali apoptosis 
kit. For image reading, 25 µL of treatment material was 
dispensed onto specific plates and cell viability was 
assessed by green/red fluorescence.
RESULTS AND DISCUSSION
Preparation and characterization of hydrogels 
with and without bupropion
While preparing the hydrogels, ensuring a 24 h rest 
time at 10 °C was critical for full removal of air bubbles 
formed during the hydration of polymers and mixing of 
components. Table III shows hydrogel pH and viscosity 
values, expressed as means (n = 3). Formulations F1, F2, 
F3, and F4 are described in Table I. Formulation 4A and 
Mixture A correspond, respectively, to the apical layer and 
the basal layer of the bilayer films. The other formulations 
were used as placebos in the composition of films, to 
allow the influence of bupropion on the physicochemical 
features of hydrogels and films to be investigated, as well 
as their cytotoxicity.
Bupropion changed hydrogel pH values when used 
at a concentration of 27% (F4A), but did not significantly 
alter pH values when employed at 9% (F3A and Mixture 
A). The formulations containing bupropion (F3A, F4A, 
and Mixture A) exhibited reduced viscosity, probably due 
to their acidic character.
Preparation and characterization of hydrogel films
The technique employed for obtaining hydrogel 
films using acrylic dispensers on a glass plate proved 
suitable for bilayer films, ensuring homogeneous physical 
characteristics and appearance. Mean weight and thickness 
of 9 cm2 film pieces were 236.25 mg ± 0.5 mm and 
0.08 mg ± 0.05 mm, respectively.
Mechanical strength properties of bilayer films
Mechanical strength data are shown in Table IV and 
Figures 1a-d. Burst strength, relaxation, and resilience tests 
measure film ability to resist compression, while traction 
strength test measures the ability to resist elongation.
The results of the burst strength test (Figure 1a), 
which measures compressive strength as a function 
of time, revealed, as expected, that bilayer films are 
mechanically stronger than monolayer films. In the 
presence of bupropion, however, mechanical strength was 
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reduced, for both types of film. Presence of bupropion 
in crystalline or amorphous form dispersed in the 
polymer matrix decreased polymer reticulation affecting, 
negatively, the mechanical strength of films. Presence of 
bupropion decreased burst strength resistance by 62.72% 
and 64.04% in monolayer and bilayer films, respectively. 
In the absence of bupropion, bilayer films were 63.04% 
more resistant than monolayer films. Presence of 
bupropion caused the resistance of bilayer films to be 
69.49% higher than in monolayer films.
Among the mechanical properties of polymer films, 
mechanical relaxation is the least investigated. Relaxation 
curves (Figure 1b) depict film viscoelasticity, an important 
property that provides information directly related to the 
conformation of macromolecules and molecular relaxation 
phenomenon (Ferry, 1980; Chandra, Sobral, 2000). The 
results shown in Figure 1b reveal significant differences 
between monolayer and bilayer films. Compared with 
monolayer films, bilayer films promote changes in the 
macromolecular conformation of polymers, increasing 
film resistance by roughly 55%. Irrespective of bupropion 
content, however, the difference between monolayer and 
bilayer films was of only 10%. In Figure 1b, the ascending 
curve is a result of the deformation constant. After 4 s, the 
force applied was not sufficient to maintain deformation. 
This behavior is characteristic of viscoelastic materials.
FIGURE 1 - Mechanical strength (a) Burst strength; (b) Relaxation; (c) Resilience; (d) Traction. BB (bilayer bupropion); PB 
(placebo bilayer); BM (bupropion monolayer); PM (placebo monolayer).
TABLE IV – Values (means ± SD) obtained for bilayer films (with and without bupropion) and monolayer (with and without 
bupropion), subjected to strength test
Films Burst strength (kg) Relaxation (kg) Resilience (kg) Traction (kg)
Mixture A + F4A 2.878 ± 0.215 1.757 ± 0.023 1.740 ± 0.106 4.992 ± 0.072
Mixture B + F4B 7.720 ± 0.422 1.910 ± 0.015 1.456 ± 0.076 4.142 ± 0.212
Mixture A 1.698 ± 0.179 0.958 ± 0.108 0.878 ± 0.049 2.348 ± 0.319
Mixture B 4.722 ± 0.624 1.053± 0.097 0.894 ± 0.022 2.360 ± 1.639
A novel dosage form for buccal administration of bupropion 97
In the presence of bupropion, elastic deformation 
of the bilayer films was 50.46% higher than in monolayer 
films. In bilayer films containing bupropion, elastic 
deformation was 26.32% higher than in bilayer films 
devoid of bupropion. Elastic deformation was 0,894 kg s–1 
in monolayer films containing bupropion and 0,878 kg s–1 
in those devoid of drug.
Figure 1d shows the mechanical tensile strengths 
of monolayer and bilayer films with and without 
bupropion. Bilayer films, as expected, exhibited greater 
resistance to rupture than monolayer films. The presence 
of bupropion in bilayer films decreased tensile strength 
by 17.03%. In monolayer films, the yield stress of films 
containing bupropion was higher than in those devoid of 
drug. However, the yield strength of mono- and bilayer 
films containing bupropion was 0.51% lower than for 
monolayer films devoid of drug. The results obtained for 
tensile yield strength are characteristic of ductile materials. 
Malleability and flexibility are a desirable characteristic 
of films intended for buccal application, particularly on 
the hard palate.
Morphology of hydrogel films
The SEM images selected for Figure 2 show the 
morphology of a bilayer film (panel A, apical surface 
(MA); panel B, basal surface (F4A); panels C-F, lateral 
surface at 500, 1500, 2500, and 4500× magnification)
The apical surface (MA, panel A) is deposited on the 
glass plate surface, the porosity of which makes the film 
rougher. The basal surface (F4A, panel B) is smooth, and 
the stains, invisible macroscopically, may be due to the 
mixture of polymers (CMC, HPMC K4M, MVC).
In cross-section images (CF), the division between 
layers is clearly visible. The position of the image 
corresponds to that of film placement in the oral cavity. 
The upper, lighter layer of polymer (MA) adheres to the 
palate epithelium; the lower layer consists of F4A. Placed 
in the oral cavity, the basal surface becomes prone to rapid 
erosion, allowing faster release of the drug contained in it.
In the SEM images, the apical and basal layers 
have distinctive features, confirming the characteristics 
observed macroscopically. This allows oral appliances 
in the form of bilayer films to be tested for their drug 
delivery ability.
Evaluation of bupropion content in bilayer films
Bupropion content in bilayer films was calculated 
from the straight-line equation (Table V). Figure 3 shows 
the calibration curve obtained by UV spectroscopy (λ = 
FIGURE 2 – SEM images of bilayer films: (A) upper surface; (B) 
lower surface; (C-F) cross-sections, at different magnifications.
252 nm). A linear correlation (R2 = 0.9999) was observed 
between absorbance at 252 nm and bupropion concentration 
FIGURE 3 – Analytical curve constructed from the absorbance 
values of samples.
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in the range of 20 to 180 µg/mL. Bupropion concentration 
in a 9 cm2 film piece was 121 mg, which corresponds to 
80.67% of the expected content (150 mg/film).
Cell viability
The percentages of living, apoptotic, and dead cells 
(Figure 4) showed that at 6 h of exposure the viability of 
K-562 cells dropped slightly. Cell cultures containing 
placebo monolayer films (MCP), bupropion monolayer 
films (MCB), placebo bilayer films (BCP), and bupropion 
bilayer films (BCB) exhibited vitality rates of 76%, 81%, 
67%, and 47%, respectively, while for controls the rate 
was 79%. At 6 h of exposure (Figure 5) the rates of cell 
death were 20% (controls), 7% (MCP), 11% (MCB), 30% 
(BCP), and 10% (BCB).
Low cell death rates are expected at the beginning of 
treatment, since the cells are adapting to the new conditions. 
In this study, cell death rates for cells receiving MCP, MCB 
and BCB were lower than for controls. For those receiving 
BCB, death rate at 6 h was 50% higher than for controls. 
The results show that bupropion contents of up to 150 mg 
per 9 cm2 of film (BCB) failed to induce cell death.
At 24 h of exposure, the cell vitality rate increased, 
while death and apoptosis rates decreased (Figure 4), 
revealing that the cells recovered vitality after the initial 6 h 
of exposure. Based on the vitality of controls (94%), if can 
be concluded that cells exposed to MCB (96%) and BCP 
(92%) behaved similarly and that polymer concentrations 
in the monolayer and bilayer films do not influence cell 
behavior. The lower growth rate observed in cells exposed to 
BCB can be explained by a higher concentration of residues 
from the cell-growth medium. For cells exposed to MCP, 
the viability index at 24 h of exposure (79%) cannot be 
explained, since no cell death occurred (Figure 4).
Death rates for controls and cells exposed to MCB, 
BCP, and BCB were 5%, 7%, 9%, and 17%, respectively 
(Figure 4), with no significant differences between 
controls and cells exposed to MCB or BCP. In contrast, 
the death rate of cells exposed to BCB was roughly 3 times 
as high as for controls.
Apoptosis rates of cells exposed to MCB (5%) and 
BCP (6%) were similar to those of controls (4%), while 
those of cells treated with MCP (20%) and BCB (27%) 
were 5 to 7 times as high as for other cells. The results 
obtained for films devoid of bupropion (MCP and BCP) 
cannot be explained by the residual concentration of 
polymers in the culture medium, since the mass of the 
monolayer placebo films (MCP) was less than 10% that of 
bilayer placebo films (BCP). Figure 5 shows values of cell 
viability as a function of time, revealing steady growth, 
equivalent to that of controls.
The higher death rates found among cells exposed 
to bupropion and the viability rates along time suggest the 
presence of a stimulus for cell division, because despite 
the higher death rate among treated cells, the number of 
cells per milliliter remained high. Cell morphology was 
evaluated at 24 h of treatment, revealing no morphological 
differences between controls and cells exposed to BCP or 
BCB (Figure 6). Presence of cell divisions was indicative 
of a normal division process.
The cytotoxicity results showed that monolayer and 
bilayer films containing bupropion are safe for human 
use, as they did not cause cell damage. The results for cell 
FIGURE 4 – Results obtained with image cytometer at 6 and 
24 h of exposure.
FIGURE 5 – Cell viability vs. time, for different treatments.
TABLE V – Analytical parameters of the calibration curve
Parameters Values
Angle of inclination with respect to 
the X axis
0.004
Point of intersection with the Y axis 0.0181
Coefficient of linearity (R²) 0.9999
Equation of the slope y = 0.004x + 0.0181
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FIGURE 6 – K-562 cells at 24 h of exposure. Top row: living 
cells. Bottom row: cells fixed and stained with Giemsa after test 
completion. (A) Controls. (B) Placebo bilayer film. (C) Bilayer 
film containing bupropion.
death and apoptosis at 6 and 24 h were irrelevant, since 
film permanence times in the oral cavity are necessarily 
shorter than those evaluated in the present study.
CONCLUSIONS
Hydrogel films for oral administration of drugs 
have low cost of production, and their physicochemical 
and biological quality control costs are also low. Easy to 
carry and to administer, they constitute a useful resource 
to improve adherence to smoking cessation treatments. 
The technique employed in the present study to prepare 
the films proved practical, reproducible, and scalable. The 
macroscopic characteristics of films were satisfactory, both 
physically and in sensory terms. The values obtained for 
the mechanical properties show that the films can be easily 
handled during cutting and packaging. The cytotoxicity 
tests demonstrated the biological safety of the product. 
Further studies are necessary to evaluate release profiles 
and mucoadhesive strength values, for biopharmaceutical 
characterization of the films.
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